HITK - Huge play IMH - reported 0.45 for the Q, way above the analyst estimate of 0.20 - 13 products in FDA approval, 20 products under development, sector PE average 30 and they may be floating around 4-7 forward PE with no debt. At current earnings rate, this has all the rights to be valued $50 or higher.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.